ALXO ALX Oncology Holdings Inc.

NASDAQ
$1.96

ALX Oncology Holdings Inc. (ALXO) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.0% since its last earnings release on August 6, 2026.

ALX Oncology Beat Consensus Estimates
Thursday, August 6, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($0.15)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.06

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

Sector

Healthcare

Industry

Biotechnology